Compare UFG & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UFG | ALLR |
|---|---|---|
| Founded | 2021 | 2004 |
| Country | Singapore | United States |
| Employees | 17 | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.7M | 25.6M |
| IPO Year | N/A | 2021 |
| Metric | UFG | ALLR |
|---|---|---|
| Price | $0.82 | $1.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 224.8K | ★ 227.3K |
| Earning Date | 04-22-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $320,000.00 |
| Revenue This Year | $3.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $211.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $0.77 |
| 52 Week High | $9.91 | $2.35 |
| Indicator | UFG | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 49.68 | 45.55 |
| Support Level | $0.63 | $1.29 |
| Resistance Level | $0.85 | $1.80 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 33.72 | 31.91 |
Uni-Fuels Holdings Ltd is a service provider of marine fuels solutions. The company market, resell and brokers marine fuels products such as VLSFO, HSFO, and MGO. It offers these products to shipping companies and marine fuels suppliers in-port and offshore. In addition, the company may from time to time provide shipping-related services to its customers including but not limited to the arrangement of ship agents, ship provisions and marine fuels surveyors. It operates an integrated business model where It serves its customers through two operating models, sales of marine fuels solutions and brokerage.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.